WCLC 2025 - Posters & ePosters-P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis

P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis

Back to course

Pdf Summary

This retrospective single-center analysis reports on the long-term efficacy of immune checkpoint inhibitors (ICIs) in treating pulmonary cancers with rhabdoid features (PCRF), a rare and aggressive lung cancer subtype with poor prognosis and limited molecular data. The study includes three patients treated with ICIs at the Lausanne University Hospital (CHUV).<br /><br />All three PCRF patients demonstrated high PD-L1 expression (90-100%), a biomarker associated with response to ICIs. Patient 1, a 53-year-old man with metastatic disease (stage IVB), received pembrolizumab monotherapy, achieving a durable complete response and remains disease-free seven years post-treatment initiation. Patient 2, a 64-year-old man with stage IVB disease harboring a KRAS G12C mutation and PD-L1 100%, was treated with carboplatin, paclitaxel, and pembrolizumab, achieving complete response; after 18 months, localized adrenal recurrence was managed with stereotactic radiotherapy, and he remains disease-free 3.5 years after starting treatment. Patient 3, a 65-year-old woman with stage IIIA disease and high PD-L1 (95%), underwent surgery, adjuvant chemotherapy, then chemoradiotherapy followed by durvalumab after relapse, achieving complete response, but later died due to metastatic renal carcinoma.<br /><br />This is the first report documenting prolonged and durable responses to ICIs in PCRF patients, highlighting potential efficacy despite the cancer's aggressive nature. The findings suggest that high PD-L1 expression in PCRF may predict benefit from immunotherapy. The study emphasizes the need for further molecular characterization and clinical research to understand PCRF biology better and optimize therapeutic strategies.<br /><br />In summary, ICIs demonstrated promising long-term control in select PCRF cases, offering hope for this rare and challenging lung cancer variant. Further studies are warranted to validate these findings and explore molecular targets for therapy.

Asset Subtitle

May-Lucie Meyer

Meta Tag

Speaker May-Lucie Meyer

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immune checkpoint inhibitors

pulmonary cancers with rhabdoid features

PCRF

PD-L1 expression

pembrolizumab

durable complete response

KRAS G12C mutation

stereotactic radiotherapy

durvalumab

lung cancer immunotherapy